AACR presentation illustrates broad potential of Antisoma's AS1411 in blood cancers
LONDON, and SAN DIEGO, Calif, 16 April 2008 - Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that new preclinical data on its anti-nucleolin aptamer drug AS1411 are presented today at the American Association for Cancer Research (AACR) meeting in San Diego, CA.
The presentation shows that AS1411 killed cells from a variety of blood cancer cell lines, including leukaemias, lymphomas and a myeloma. Among these were three Burkitt's lymphoma lines. In further experiments, these lines were treated with a combination of AS1411 and doxorubicin, a drug often used to treat Burkitt's lymphoma. The AS1411-doxorubicin combination produced synergistic (more than additive) killing of the lymphoma cells.
Positive combination data have also been obtained in AML (acute myeloid leukaemia) cell lines. Here, AS1411 was combined with cytarabine, a drug widely used in AML. A phase II trial is now evaluating the combination of AS1411 and cytarabine in AML patients. The AACR presentation extends the support for this approach from cell lines to in-vivo data. It shows that an AS1411-cytarabine combination synergistically inhibited the growth of human AML xenografts in mice.
Dr Fiona McLaughlin, Director of Research at Antisoma, said: "These new data provide further support for our AS1411-cytarabine combination trial in AML, and also illustrate the broader potential of AS1411 against a range of haematological malignancies."
Enquiries: Alison Saville, Communications Executive +44 (0)20 8799 Antisoma plc 8200
Mark Court/Lisa Baderoon/Rebecca Skye +44 (0)20 7466 Dietrich 5000 Buchanan Communications
Brian Korb +1 646 378 2923 The Trout Group
Except for the historical information presented, certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.
Notes for Editors:
Background on AS1411 Aptamers are short pieces of DNA or RNA that can fold into stable, three-dimensional structures capable of interacting with particular target proteins. AS1411 is the first aptamer to be tested as a treatment for cancer. It binds to the protein nucleolin, which is found on the surface of cancer cells. It is then internalised and has been shown to kill cancer cells from a variety of cell lines. The drug has also shown anti-cancer effects in animal models and promising signs of anti-cancer activity in the clinic. AS1411 was originally developed by Dr Paula Bates, Dr John Trent and Prof. Donald Miller at the University of Alabama and then at the University of Louisville. Antisoma added AS1411 to its pipeline when it acquired the Louisville-based company Aptamera Inc. in February 2005.
Background on Antisoma Headquartered in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information about Antisoma.
Posted: April 2008